Barclays
MIRM icon

Barclays’s Mirum Pharmaceuticals MIRM Stock Holding History

Barclays’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.68M Buy
57,018
+37,486
+192% +$3.76M ﹤0.01% 1693
2026
Q1 		$1.8M Sell
19,532
-122,612
-86% -$11.5M ﹤0.01% 2416
2025
Q4 		$11.2M Buy
142,144
+26,373
+23% +$1.89M ﹤0.01% 1608
2025
Q3 		$8.49M Sell
115,771
-39,100
-25% -$2.49M ﹤0.01% 1797
2025
Q2 		$7.88M Buy
154,871
+73,567
+90% +$3.28M ﹤0.01% 1740
2025
Q1 		$3.66M Sell
81,304
-170,660
-68% -$8.04M ﹤0.01% 2156
2024
Q4 		$10.4M Buy
251,964
+6,046
+2% +$252K ﹤0.01% 1539
2024
Q3 		$9.59M Buy
245,918
+10,824
+5% +$432K ﹤0.01% 1513
2024
Q2 		$8.04M Sell
235,094
-39,772
-14% -$1.04M ﹤0.01% 1286
2024
Q1 		$6.9M Buy
274,866
+174,944
+175% +$4.81M ﹤0.01% 1643
2023
Q4 		$2.95M Sell
99,922
-199,198
-67% -$6.03M ﹤0.01% 2576
2023
Q3 		$9.45M Buy
299,120
+11,970
+4% +$328K 0.01% 1021
2023
Q2 		$7.43M Sell
287,150
-12,313
-4% -$327K ﹤0.01% 1123
2023
Q1 		$7.19M Sell
299,463
-78,109
-21% -$1.78M ﹤0.01% 1329
2022
Q4 		$7.36M Buy
377,572
+288,695
+325% +$5.71M ﹤0.01% 1376
2022
Q3 		$1.87M Buy
88,877
+65,621
+282% +$1.58M ﹤0.01% 1795
2022
Q2 		$453K Sell
23,256
-6,063
-21% -$143K ﹤0.01% 2941
2022
Q1 		$646K Buy
+29,319
New +$598K ﹤0.01% 2716

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's MIRM Position: Q2 2026 in Review

Barclays increased its Mirum Pharmaceuticals (MIRM) stake by 192% in Q2 2026, buying an estimated $3.76M and bringing the position to 57,018 shares worth $6.68M. The position accounts for ﹤0.01% of the portfolio, ranked #1693.

Barclays first reported a position in MIRM in Q1 2022 and has held it in 18 quarters since. The position peaked at $11.2M in Q4 2025. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Barclays held 57,018 shares of Mirum Pharmaceuticals worth $6.68M as of Q2 2026.
  • Barclays bought 37,486 Mirum Pharmaceuticals shares in Q2 2026, an estimated $3.76M.
  • Mirum Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1693 holding.
  • Barclays first reported a position in Mirum Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Mirum Pharmaceuticals position peaked at $11.2M in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.